Information Provided By:
Fly News Breaks for May 30, 2018
CPRX
May 30, 2018 | 07:27 EDT
Now that Catalyst Pharmaceuticals has a PDUFA date for Firdapse following the FDA's granting of priority review, the major overhang of the past two years has been effectively lifted, H.C. Wainwright analyst Andrew Fein tells investors in a research note. The analyst believes approval is in sight and reiterates a Buy rating on the shares with a $6 price target.